The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer is a Buy, with valuation reflects LOE risks and attractive risk-reward and executes on post-LOE growth strategies. Read more on PFE stock here.

Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level. Pfizer is dealing with what are, in reality, just normal headwinds in the ...

A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Pfizer appears to be attractively valued, with high current dividend ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Pfizer(NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly technical ...

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts ...